CASTLE BIOSCIENCES INC

Insightful look at COO Kristen Oelschlager’s recent Castle Biosciences sale and what it signals for investors in a volatile biotech market.

Castle Biosciences insider trade: CEO Derek Maetzold buys 550 shares at $2.39, signaling confidence in AI diagnostics growth and long‑term partnership with investors.

CEO Derek Maetzold’s small June 1 “back‑door” purchase shows neutral confidence in Castle Biosciences, but the real upside depends on future milestones and approvals.

Castle Biosciences CEO’s rule‑based share sale: why insiders are locking in gains, what it means for investors, and how to position your portfolio.